Gary M. Tse
0000-0002-9405-9665
Publication & Citation Trends
Publications
0 total
Abstract 3094: Targeting TUBB2B: Exploiting brain metastatic vulnerabilities in triple-negative breast cancer
Cited by 0
Semantic Scholar
Calcification and tumour‐infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 ( HER2) ‐negative ductal carcinoma in situ diagnosed on core needle biopsy
Cited by 0
Semantic Scholar
Predictors of Response to Neoadjuvant Therapy in HER2-positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity.
Cited by 0
Semantic Scholar
International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-low and Ultralow Categories.
Cited by 6
Semantic Scholar
Best pathology practices for HER2 testing interpretation, including HER2-low and ultralow, in the era of HER2-directed antibody drug conjugates (ADCs), aligned with the 2018 CAP/ASCO HER2 guidelines.
Cited by 2
Semantic Scholar
WHO Classification of Tumours: evolution of a global resource in the molecular era.
Cited by 6
Semantic Scholar
Malignant phyllodes tumours of the breast: the case for revising WHO’s ‘full house’ diagnostic criteria OA
Cited by 9
Semantic Scholar
Ray-Aided Quadruple Affiliation Network for Calculating Tumor-Stroma Ratios in Breast Cancers
Cited by 1
Semantic Scholar
Research Topics
Breast Lesions and Carcinomas
(188)
Breast Cancer Treatment Studies
(130)
Cancer and Skin Lesions
(121)
Salivary Gland Tumors Diagnosis and Treatment
(65)
Cancer Cells and Metastasis
(47)
Affiliations
Università Cattolica del Sacro Cuore
University of Vermont
Canterbury Christ Church University
Beth Israel Deaconess Medical Center
Department of Health